Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
ClinicalTrials.gov · NCT06762314 · Registry updated: 2026-09-02
- Condition / research focus
- Diabetes
- Sponsor
- Mostafa Bahaa
- Countries with listed sites
- Egypt
- Registry dates and results
- Start: 2025-01-20. Completion: 2026-01-20 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Insulin (drug)
- Semaglutide (drug)
- Empagliflozin (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Tanta Unuversity
Tanta, Egypt
Site recruitment: Not reported